CJC-1295 with DAC vs Tesamorelin
Well Studied vs FDA Approved
avoid Researched · 95% Both are GHRH analogs; no additional benefit and potential receptor competition.
Molecular Data
CJC-1295 with DAC Tesamorelin
Weight 3,647.28 Da 5,135.9 Da
Half-life 6-8 days 26-38 minutes
Chain 30 amino acids 44 amino acids
Type GHRH analog with DAC GHRH analog
Key Benefits
CJC-1295 with DAC
01 Convenient weekly dosing
02 Sustained GH/IGF-1 elevation
03 6-8 day half-life
04 Significant body composition changes
Tesamorelin
01 FDA-approved formulation
02 Selective visceral fat targeting (15-20% reduction)
03 Proven clinical efficacy
04 Standardized dosing
05 37% liver fat reduction in NAFLD
06 Preserved subcutaneous fat
Dosing Protocols
CJC-1295 with DAC
1-2mg weekly / Once or twice weekly (e.g., Monday/Thursday for split dosing)
Conservative Anti-Aging 1mg Once weekly
Standard Protocol 2mg Once weekly
Split Dosing 1mg Twice weekly (Mon/Thu)
Loading Protocol 2mg first week, then 1mg Weekly
Tesamorelin
1.4-2mg daily (FDA-approved: 2mg for HIV lipodystrophy) / Once daily (evening preferred for GH rhythm)
HIV Lipodystrophy (FDA-approved) 1.4mg Once daily
Visceral Fat Reduction 2mg Once daily
Anti-aging/Body Composition 1-2mg 5-7x weekly
NAFLD Treatment 2mg Once daily (12 months)
Cognitive Enhancement 1mg Once daily (20 weeks)
Side Effects
CJC-1295 with DAC
Water retention
Joint pain
Carpal tunnel symptoms
Tesamorelin
Injection site reactions (17%)
Joint pain (13%)
Water retention
Contraindications
Diabetes history
Cancer history
Predisposed sleep apnea
Active malignancy
Pituitary disorders
Pregnancy
Research Evidence
CJC-1295 with DAC Tesamorelin
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest 2025 June 2025
FDA Approved No Yes
Full CJC-1295 with DAC profile Full Tesamorelin profile CJC-1295 with DAC calculator Tesamorelin calculator
More comparisons: Metformin
This comparison is for educational and research purposes only. Consult a healthcare professional before use.